Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Other Patients With Rare Chronic Anemia and Transfusional Iron Overload
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Deferasirox (Primary)
- Indications Iron overload
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals Corporation
Most Recent Events
- 10 Sep 2014 New trial record